CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella, a biotechnology company pioneering transformative medicines for patients with severe conditions caused by disrupted amino acid biology, announced today that Robert Connelly, President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. The presentation will take place on January 11, 2017, from 8-8:25 a.m. PST in Elizabethan D at the Westin St. Francis Hotel.
Mr. Connelly will provide an update on the company’s lead clinical candidates. The presentation will focus on leads from the company’s metabolic (including muscle and liver) and neurological programs. Both programs are part of the company’s expanding pipeline of candidates for orphan and large disease populations.
About Axcella
Axcella is pioneering a revolutionary
therapeutic modality that identifies how disturbances in amino acid
biology lead to disease. The company’s platform rapidly yields novel
molecules to restore normal amino acid homeostasis, treat disease and
reactivate healthy central metabolism. Axcella has expeditiously
translated its discoveries into molecules that have been tested in 10
clinical trials to date, with lead programs in intractable epilepsy,
NASH, and pathological atrophy. Its lead clinical candidates have
demonstrated in human and preclinical models an ability to bring
homeostasis to dysregulated cells, repair cellular function, restore
healthy pathways, and regenerate tissue and healthy organ function. The
company was founded by VentureLabs, the Innovation Foundry at Flagship
Pioneering, and has received financing from Flagship’s venture funds,
alongside co-investors Fidelity Research & Management Group, Gurnet
Point Capital and Nestlé Health Science. Axcella is based in Cambridge,
Mass. For more information, visit www.axcellahealth.com.
